Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment

[1]  E. Bateman,et al.  The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials , 2017, Trials.

[2]  Christine Jenkins,et al.  Development and validation of a novel risk score for asthma exacerbations: The risk score for exacerbations. , 2015, The Journal of allergy and clinical immunology.

[3]  M. Levy.  National Review of Asthma Deaths (NRAD). , 2014, The British journal of general practice : the journal of the Royal College of General Practitioners.

[4]  Mike Thomas,et al.  Why asthma still kills: the National Review of Asthma Deaths (NRAD)Confidential Enquiry report , 2014 .

[5]  D. Shaw,et al.  P161 A randomised controlled trial of single combination budesonide/formoterol inhaler as maintenance and reliever therapy in asthma patients at risk of severe exacerbations , 2013, Thorax.

[6]  D. Shaw,et al.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[7]  E. Burchard,et al.  Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. , 2011, The Journal of allergy and clinical immunology.

[8]  C. Jenkins,et al.  Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps , 2011, Respiratory research.

[9]  Christine Jenkins,et al.  Overall asthma control: the relationship between current control and future risk. , 2010, The Journal of allergy and clinical immunology.

[10]  L. Lynd,et al.  Direct health care costs associated with asthma in British Columbia. , 2010, Canadian respiratory journal.

[11]  B. van Ginneken,et al.  Chest , 2009, Indian Journal of Radiology and Imaging.

[12]  R. Leigh,et al.  A Holy Grail of asthma management: toward understanding how long‐acting β2‐adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids , 2008, British journal of pharmacology.

[13]  P. O'Byrne,et al.  Pharmacological management of mild or moderate persistent asthma , 2006, The Lancet.

[14]  K. Rabe,et al.  Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. , 2006, Chest.

[15]  H. Bisgaard,et al.  Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. , 2005, American journal of respiratory and critical care medicine.

[16]  L. Boulet,et al.  Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma , 2004, Current medical research and opinion.

[17]  Kevin B Weiss,et al.  Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. , 2004, The Journal of allergy and clinical immunology.

[18]  Brigit VanGraafeiland,et al.  National Asthma Education and Prevention Program. , 2002, The Nurse practitioner.

[19]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[20]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[21]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[22]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[23]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[24]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[25]  C. Robertson,et al.  Pediatric asthma deaths in Victoria: The mild are at risk , 1992, Pediatric pulmonology.

[26]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[27]  Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. , 2007, The Journal of allergy and clinical immunology.

[28]  J. Papadimitriou,et al.  Current Medical Research and Opinion , 2004 .

[29]  P. J. Barnes.  Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. , 2002, The European respiratory journal.

[30]  J. McNeil,et al.  Are asthma medications and management related to deaths from asthma? , 2001, American journal of respiratory and critical care medicine.

[31]  R. Klocke,et al.  THE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE , 1994 .